SP Tulsian of sptulsian.com told CNBC-TV18, "I will go with Wockhardt. Now one can see relief coming in on their Waluj plant for USFDA. I have very big confidence in the management. Prior to this all negative news coming in, it is a Rs 150 EPS company and the stock has corrected from Rs 2,200 to a low of about Rs 400 or Rs 400 plus. In the past also when I identified the stock at Rs 100 and then gave a repeated call at Rs 300-400, so obviously confidence gets reinforced."
"In case of Orchid Chemicals and Pharmaceuticals nothing has really materialised in their favour. The main focus should be on the control or reduction of the debt which they have not been able to do and maybe again the margin on their Cephalosporin business has been shrinking. So I will not be going with the Orchid though the stock has moved in these last 3-4 days. Wockhardt can be a pick at this stage now," he said.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
